4
Changes in Ownership
Kalaris Therapeutics, Inc. Filed Acc 0000899243-22-025233
Chief Commercial Officer sold 515 shares at $3.63 ($1,871)
- Chief Commercial Officer acquired 14,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
VAN BEEK JEROEN B · Chief Commercial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2022-06-03 | Sale : show line 1 in the form | −515 | $3.63 | $1,871 | 389,011 | D |
| 2022-07-01 | Grant or award : show line 2 in the form | +14,000 | 403,011 | D | ||
| Open-market sales · 515 sh · avg $3.63 · $1,871 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2022-07-01 | Grant or award : show line 3 in the form Stock Option (Right to Buy) | +26,000 | $4.13 | 2032-07-01 | 26,000 | 26,000 | D |
Loading xslF345X03/doc4.xml…